Patient centricity is a priority for Merck and its Executive Vice President and Head of EMEA Region, Chris Round, outlines what practical steps the company is taking to improve life for patients and carers.
Merck & Co's cancer drug Keytruda has been granted a priority review so that the immunotherapy medicine can be used in conjunction with chemotherapy to improve survival rates for untrea
As part of pharmaphorum’s eye-on-innovation interview series, Paul Tunnah speaks to Merck Biopharma’s vice president of innovation Ulrich Betz on how the company is celebrating its 350th